Thymosin Alpha 1.

Thymosin Alpha 1 is an investigational compound in the thymic & immune-modulating peptides.

Modulating immune-cell activity and inflammation.

It draws interest for thymic & immune-modulating peptides.

C-tier evidence: some human evidence exists but isn't definitive.

What it is

Thymosin alpha-1 (Tα1, international nonproprietary name thymalfasin; brand name Zadaxin) is a synthetic 28-amino-acid acetylated peptide identical to a naturally occurring fragment derived from prothymosin alpha, a protein produced in the thymus. It belongs to the thymosin family of thymic-derived peptides and is one of the most clinically studied immunomodulatory peptides, marketed as a prescription immune modulator in numerous countries outside the United States.

How it works

Tα1 is an immune modulator rather than a simple immune stimulant: it acts largely through Toll-like receptors, principally TLR2 and TLR9, on dendritic cells, monocytes/macrophages, and other antigen-presenting cells. Downstream MyD88-dependent signaling promotes dendritic cell maturation, biases naive T cells toward Th1 differentiation, augments natural killer cell and cytotoxic T-cell activity, and can modulate regulatory pathways including indoleamine 2,3-dioxygenase. In settings of immune exhaustion or sepsis-associated immunoparalysis, the proposed benefit is restoration of T-lymphocyte numbers and function (e.g., raising depleted CD4+/CD8+ counts and reducing markers of T-cell exhaustion) rather than broad immune activation.

What the evidence shows

Human evidence is most developed in chronic hepatitis B and as an adjunct in sepsis, but is mixed and often comes from China-based studies of variable quality. The largest dedicated sepsis trial, ETASS (Wu et al., Critical Care 2013, a multicenter single-blind RCT of 361 patients with severe sepsis), found a reduction in 28-day all-cause mortality that did not reach statistical significance, so its primary endpoint was formally negative; subsequent systematic reviews (e.g., Liu et al., BMC Infect Dis 2016) noted possible mortality benefit but flagged small sample sizes, heterogeneity, and risk of bias. In COVID-19, the widely cited Liu et al. (Clin Infect Dis 2020) report associating Tα1 with lower mortality was a retrospective review of only 76 severe cases, not a randomized trial, and cannot establish efficacy. For hepatitis B, meta-analyses (e.g., entecavir plus Tα1 in HBV-related cirrhosis, BMC Gastroenterol 2020) suggest possible adjunctive benefit on virologic and immune endpoints but again rest on heterogeneous trials; high-quality Western regulatory trials have not confirmed a clear benefit. Much of the broader "immune-restoring" and anti-cancer rationale remains preclinical or mechanistic.

Safety considerations

Across decades of clinical use as thymalfasin, Tα1 has generally been reported as well tolerated, with injection-site reactions among the more commonly noted effects; it is a peptide given by injection in studied settings. Because its action is immunomodulatory, theoretical and context-dependent concerns include effects in autoimmune disease, transplant recipients, or other immune-sensitive populations, and immunogenicity is one reason regulators have scrutinized compounded versions. Importantly, much safety data comes from regulated pharmaceutical product used under medical supervision; the purity, identity, and safety of research-grade or compounded "gray market" material are not assured, and long-term safety outside approved indications is not well characterized.

Regulatory status

Thymalfasin (Zadaxin) is approved and marketed as a prescription drug in roughly 30-plus countries (including China, Italy, and parts of Asia, Latin America, and the Middle East), chiefly for chronic hepatitis B and as an immune adjunct, but it is NOT approved by the US FDA or centrally by the EMA; in the US it has held orphan-drug designations and been studied investigationally. In US compounding, FDA placed thymosin alpha-1 in Category 2 of the interim 503A bulk substances list in 2023 (citing safety/data concerns), and in 2024 it was removed from Category 2 after its nomination was withdrawn, leaving it without a clear compounding pathway.

1. [1]The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — Critical Care, 2013; PMID 23327199
2. [2]The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials — BMC Infectious Diseases, 2016; PMID 27633969
3. [3]Thymosin Alpha 1 Reduces the Mortality of Severe COVID-19 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells — Clinical Infectious Diseases, 2020 (retrospective, n=76); PMID 32442287
4. [4]Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (interim list categories) — U.S. Food and Drug Administration, regulatory page

• Regulatory status varies by country; US use is research/compounded.
• “Boosts immunity” in healthy people is not an established benefit.

Stack fit

Why not B: held back by remaining gaps and limited replication.

Why not D: supported by its overall evidence profile.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• Thymosin Alpha 1 is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Thymic & immune-modulating peptides class.
• Its principal mechanism is characterized in the literature.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The Thymic & immune modulation mechanism
3. The preclinical evidence lane
4. Why Early, and not higher or lower
5. Proven lane vs speculative lane
6. What people report
7. Regulatory status
8. What changed recently